Document Detail


A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.
MedLine Citation:
PMID:  18307562     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hypereosinophilic syndrome (HES) is defined as chronic, unexplained hypereosinophilia with organ involvement. A subset of HES patients presents an interstitial deletion in chromosome 4q12, which leads to the expression of an imatinib-responsive fusion gene, FIP1L1-PDGFRA. These patients are diagnosed as chronic eosinophilic leukaemia (CEL). We treated seven CEL and HES patients, six of which expressed FIP1L1-PDGFRA, with imatinib using initial daily doses ranging from 100 to 400 mg. In a remission maintenance phase, the patients were treated with imatinib once weekly. All imatinib-treated patients achieved a complete haematological remission (CHR), and five of the six patients with FIP1L1-PDGFRA expression exhibited molecular remission. The decreased imatinib doses were as follows: 200 mg/week in three patients, 100 mg/week in two patients and 100 mg/d in the remaining two patients. For remission maintenance, imatinib doses were set at 100 mg/week in five patients and 200 mg/week in two patients. At a median follow-up of 30 months all patients remained in CHR and FIP1L1-PDGFRA expression was undetectable in five of the six FIP1L1-PDGFRA-expressing patients. These data suggest that a single weekly dose of imatinib is sufficient to maintain remission in FIP1L1-PDGFRA- positive CEL patients.
Authors:
Grzegorz Helbig; Beata Stella-Hołowiecka; Mirosław Majewski; Małgorzata Całbecka; Jolanta Gajkowska; Ryszard Klimkiewicz; Andrzej Moskwa; Janina Grzegorczyk; Monika Lewandowska; Jerzy Hołowiecki
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2008-02-26
Journal Detail:
Title:  British journal of haematology     Volume:  141     ISSN:  1365-2141     ISO Abbreviation:  Br. J. Haematol.     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-03-20     Completed Date:  2008-06-11     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  England    
Other Details:
Languages:  eng     Pagination:  200-4     Citation Subset:  IM    
Affiliation:
Department of Haematology and Bone Marrow Transplantation, Silesian Medical University, Katowice, Poland. ghelbig@o2.pl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Biological Markers / blood
Chronic Disease
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Hypereosinophilic Syndrome / blood,  drug therapy*
Male
Middle Aged
Oncogene Proteins, Fusion / blood*
Piperazines / administration & dosage*,  therapeutic use
Protein Kinase Inhibitors / administration & dosage*,  therapeutic use
Protein-Tyrosine Kinases / antagonists & inhibitors
Pyrimidines / administration & dosage*,  therapeutic use
Receptor, Platelet-Derived Growth Factor alpha / blood*
Remission Induction
Treatment Outcome
mRNA Cleavage and Polyadenylation Factors / blood*
Chemical
Reg. No./Substance:
0/Biological Markers; 0/FIP1L1-PDGFRA fusion protein, human; 0/Oncogene Proteins, Fusion; 0/Piperazines; 0/Protein Kinase Inhibitors; 0/Pyrimidines; 0/mRNA Cleavage and Polyadenylation Factors; 152459-95-5/imatinib; EC 2.7.10.1/Protein-Tyrosine Kinases; EC 2.7.10.1/Receptor, Platelet-Derived Growth Factor alpha

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Thalidomide in advanced mastocytosis.
Next Document:  Outcome of unrelated donor stem cell transplantation for children with severe aplastic anemia.